Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
暂无分享,去创建一个
M. D. Leibowitz | J. Berger | T. Doebber | N. Hayes | R. Smith | R. Saperstein | P. Bailey | C. Biswas | C. Cullinan
[1] M. D. Leibowitz,et al. Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .
[2] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[3] J. Berger,et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. , 1995, Endocrinology.
[4] J. Auwerx,et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.
[5] B. Blumberg,et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. , 1995, Gene expression.
[6] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[7] M. Swanson,et al. Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism , 1994, Molecular and Cellular Endocrinology.
[8] B. Spiegelman,et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[10] B. Spiegelman,et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. , 1994, Endocrinology.
[11] M. Rao,et al. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.
[12] I. Issemann,et al. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. , 1993, Journal of molecular endocrinology.
[13] H. Lebovitz. Insulin-mimetic and insulin-sensitizing drugs. , 1993, Diabetes research and clinical practice.
[14] A. Mahfoudi,et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[15] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[16] D. Edwards,et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.
[17] K. Umesono,et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.
[18] R. Ulrich,et al. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. , 1992, Molecular pharmacology.
[19] I. Issemann,et al. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.
[20] H. Ikeda,et al. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. , 1990, Arzneimittel-Forschung.
[21] F. Yoshimura,et al. Variation in enzymatic transient gene expression assays. , 1989, Analytical biochemistry.
[22] J. Wilson,et al. Characterization and expression of a cDNA encoding the human androgen receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[23] H. Mitsui,et al. Preadipocyte differentiation in vitro: Identification of a highly active adipogenic agent , 1988, Journal of cellular physiology.
[24] S. Efendić. Pathogenesis of NIDDM. , 1988, Diabetes research and clinical practice.
[25] H. Iwatsuka,et al. Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent , 1983, Diabetes.